Centre Medico Chirurgical Ambroise Pare Hartmann
- Address
- lock Available on a paid plan
Oncology and Neoplasms
At Centre Medico Chirurgical Ambroise Pare Hartmann, the oncology research portfolio focuses on colorectal cancer and metastatic breast cancer, with studies aimed at improving treatment effectiveness, refining surgery-related strategies, and identifying which patients are most likely to benefit from specific cancer therapies.
- Locally advanced colon carcinoma, with research comparing pre-surgical treatment approaches to surgery alone
- HR+, HER2- metastatic breast cancer, using blood-based tumor DNA signals to guide treatment selection
- ctDNA-guided care in colorectal cancer, assessing how to better tailor therapy after surgery
This activity reflects a strong emphasis on personalized cancer care, especially through tumor DNA testing and treatment optimization for patients with digestive tract cancers.
Digestive System Diseases
The site also conducts clinical trials in digestive system diseases, mainly Crohn's disease and ulcerative colitis, with an emphasis on evaluating new therapies that may improve symptom control, intestinal healing, and overall disease management.
- Moderately to severely active ulcerative colitis, studying new options to improve safety and effectiveness
- Crohn's disease, with research focused on reducing inflammation and supporting better clinical response
- Ulcerative colitis, including comparisons against placebo to assess symptom and endoscopic improvement
These studies show an active interest in advancing treatment choices for chronic inflammatory bowel conditions, supporting more effective care for patients at the Centre Medico Chirurgical Ambroise Pare Hartmann.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 8 therapeutic areas and 15 of 79 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 73 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 20 by active trials.
- 1Janssen Cilag International3active
lock +19 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International8trials
lock +11 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Medico Chirurgical Ambroise Pare Hartmann
lock Showing 1 of 58 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Participants Followed by a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study in Participants with Moderate-to-Severe Active Ulcerative Colitis. | Xencor Inc. | Phase II | Recruiting | Jan 2026 | — |
IMP list
lock Showing 1 of 79 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Guselkumab | 7 | Unknown | 2022-11-30 | 2026-06-11 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.